The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer
Open accessAbstract
Purpose: The ETS2 transcription factor is an evolutionarily conserved gene that is deregulated in cancer. We analyzed the transcriptome of lung adenocarcinomas and normal lung tissue by expression profiling and found that ETS2 was significantly downregulated in adenocarcinomas. In this study, we probed the yet unknown functional role of ETS2 in lung cancer pathogenesis. Experimental Design: Lung adenocarcinomas (n = 80) and normal lung tissues (n = 30) were profiled using the Affymetrix Human Gene 1.0 ST platform. Immunohistochemical (IHC) analysis was conducted to determine ETS2 protein expression in non–small cell lung cancer (NSCLC) histologic tissue specimens (n = 201). Patient clinical outcome, based on ETS2 IHC expression, was statistically assessed using the log-rank and Kaplan–Meier tests. RNA interference and overexpression strategies were used to assess the effects of ETS2 expression on the transcriptome and on various malignant phenotypes. Results: ETS2 expression was significantly reduced in lung adenocarcinomas compared with normal lung (P < 0.001). Low ETS2 IHC expression was a significant predictor of shorter time to recurrence in NSCLC (P = 0.009, HR = 1.89) and adenocarcinoma (P = 0.03, HR = 1.86). Moreover, ETS2 was found to significantly inhibit lung cancer cell growth, migration, and invasion (P < 0.05), and microarray and pathways analysis revealed significant (P < 0.001) activation of the HGF pathway following ETS2 knockdown. In addition, ETS2 was found to suppress MET phosphorylation and knockdown of MET expression significantly attenuated (P < 0.05) cell invasion mediated by ETS2-specific siRNA. Furthermore, knockdown of ETS2 augmented HGF-induced MET phosphorylation, cell migration, and invasion. Conclusion(s): Our findings point to a tumor suppressor role for ETS2 in human NSCLC pathogenesis through inhibition of the MET proto-oncogene. Clin Cancer Res; 19(13); 3383–95. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 1×
“ZEB1 and SNAI2 (also known as SLUG) are transcription factors with well-established roles in promotion of EMT in various physiologic and pathologic conditions (22).”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086 · cited 3×
“SPDEF (also known as PDEF), amember of the ETS-domain protein family (5), was shown to be upregulated in mammary tumors (35) and to positively control cancer cell migration and invasion (36).”
BackgroundPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Yang, B.-S., Hauser, C. A., Henkel, G., Colman, M. S., Beveren, C. V., Stacey, K. J., Hume, D. A., Maki, R. A., & Ostrowski, M. C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.2.538 · Cited by 333
Ets1 and ets2 are required for endothelial cell survival during embryonic angiogenesis
Wei, G., Srinivasan, R., Cantemir-Stone, C. Z., Sharma, S. M., Santhanam, R., Weinstein, M., Muthusamy, N., Man, A. K., Oshima, R. G., Leone, G., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211391 · Cited by 185 · cited 1×
“During embryonic development, ETS2 was shown to insure proper development of the trophoblast (6) and to regulate endothelial cell survival during embryonic angiogenesis (7).”
Background
Cited by
Sun, M., Nie, F., Wang, Y., Zhang, Z., Hou, J., He, D., Xie, M., Xu, L., De, W., Wang, Z., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0356 · Cited by 469
Characterization of HPV and host genome interactions in primary head and neck cancers
Parfenov, M., Pedamallu, C. S., Gehlenborg, N., Freeman, S. S., Danilova, L., Bristow, C. A., Lee, S., Hadjipanayis, A. G., Ivanova, E. V., Wilkerson, M. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416074111 · Cited by 384
Self-citationPredictability of human differential gene expression
Crow, M., Lim, N., Ballouz, S., Pavlidis, P., & Gillis, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802973116 · Cited by 117
Liu, X., Zhang, C., Zhang, Z., Zhang, Z., Ji, W., Cao, S., Cai, X., Lei, D., & Pan, X. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2296 · Cited by 19
Metadata
- Authors
- Kabbout, M., Garcia, M. M., Fujimoto, J., Liu, D. D., Woods, D., Chow, C.-W., Mendoza, G., Momin, A. A., James, B. P., Solis, L., Behrens, C., Lee, J. J., Wistuba, I. I., & Kadara, H.
- Venue
- Clinical Cancer Research
- Published
- 2013-06-30
- Volume
- 19
- Issue
- 13
- Pages
- 3383-3395
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1992137695
- Cited by
- 192
- References
- 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-0341
- The paper
- Kabbout, M., Garcia, M. M., Fujimoto, J., Liu, D. D., Woods, D., Chow, C.-W., Mendoza, G., Momin, A. A., James, B. P., Solis, L., Behrens, C., Lee, J. J., Wistuba, I. I., & Kadara, H. (2013). ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-0341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.